ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS

Launched by FUTURE UNIVERSITY IN EGYPT · Jan 9, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether folic acid can help reduce hot flashes in women who have breast cancer and are undergoing a specific type of treatment called adjuvant endocrine therapy. Hot flashes can be quite bothersome, and the goal of this study is to see if taking folic acid can make a difference in how often and how severely these hot flashes occur.

To participate in this trial, you need to be a woman over 18 years old who has been diagnosed with breast cancer and is currently receiving adjuvant endocrine therapy. You should be experiencing at least 14 hot flashes a week, and your treatment should have started within the last six months to two years. However, if you have certain health conditions or are taking other medications that might interfere with the study, you may not be eligible. The trial is not yet recruiting participants, but it aims to provide valuable information about managing hot flashes for women going through breast cancer treatment.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Females older than 18 years
• • Diagnosed with confirmed breast cancer and currently treated with an adjuvant endocrine
• • Experiencing bothersome hot flashes at least 14 times/week
• • Taking the treatment within 6 months to two years.
• Exclusion Criteria:
• • Known hypersensitivity to folic acid
• • Patients who have been treated with selective serotonin reuptake inhibitors (SSRIs) within the past 30 days.
• • Renal impairment is defined as a serum creatinine level greater than 2 mg/ld..
• • Significant liver disease: Indicated by liver enzyme levels exceeding two times the upper limit of normal.
• • Metastatic breast cancer
• • Taking other medication for hot flashes
• • Medications inducing hot flashes such as (Clomiphene, Opioids, Nifedipine, Prednisone)